ROCKET PHARMACEUTICALS INC (RCKT) Forecast, Price Target & Analyst Ratings

NASDAQ:RCKT • US77313F1066

Current stock price

3.77 USD
-0.92 (-19.62%)
At close:
3.8 USD
+0.03 (+0.8%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ROCKET PHARMACEUTICALS INC (RCKT).

Forecast Snapshot

Consensus Price Target

Price Target
$8.37
+ 121.98% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 6, 2026
Period
Q1 / 2026
EPS Estimate
-$0.42
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
74.29%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$8.37
Upside
+ 121.98%
From current price of $3.77 to mean target of $8.37, Based on 21 analyst forecasts
Low
$3.03
Median
$9.18
High
$16.80

Price Target Revisions

1 Month
0.00%
3 Months
-2.12%

Price Target Summary

21 Wall Street analysts provided a forecast for the next 12 months for RCKT. The average price target is 8.37 USD. This implies a price increase of 121.98% is expected in the next year compared to the current price of 3.77.
The average price target has been revised downward by 2.12% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

RCKT Current Analyst RatingRCKT Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6

Analyst Ratings History

RCKT Historical Analyst RatingsRCKT Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10 15 20

Analyst Ratings Consensus

ChartMill Buy Consensus
74.29%
RCKT was analyzed by 21 analysts. The buy percentage consensus is at 74. So analysts seem to be have mildly positive about RCKT.
In the previous month the buy percentage consensus was at a similar level.
RCKT was analyzed by 21 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-27Chardan CapitalMaintains Buy -> Buy
2026-03-02Goldman SachsMaintains Sell -> Sell
2026-02-27Cantor FitzgeraldMaintains Overweight -> Overweight
2025-11-18JP MorganDowngrade Overweight -> Underweight
2025-11-18B of A SecuritiesMaintains Buy -> Buy
2025-10-14Chardan CapitalMaintains Buy -> Buy
2025-10-03Leerink PartnersMaintains Market Perform -> Market Perform
2025-08-20Chardan CapitalMaintains Buy -> Buy
2025-08-20B of A SecuritiesUpgrade Neutral -> Buy
2025-08-11Chardan CapitalMaintains Buy -> Buy
2025-08-08Cantor FitzgeraldMaintains Overweight -> Overweight
2025-07-25Canaccord GenuityMaintains Buy -> Buy
2025-07-25B of A SecuritiesDowngrade Buy -> Neutral
2025-07-24Chardan CapitalMaintains Buy -> Buy
2025-07-24NeedhamMaintains Hold -> Hold
2025-06-17UBSMaintains Buy -> Buy
2025-06-03Canaccord GenuityMaintains Buy -> Buy
2025-05-28Leerink PartnersDowngrade Outperform -> Market Perform
2025-05-28Chardan CapitalMaintains Buy -> Buy
2025-05-28ScotiaBankMaintains Sector Outperform -> Sector Outperform
2025-05-28BMO CapitalMaintains Outperform -> Outperform
2025-05-28B of A SecuritiesMaintains Buy -> Buy
2025-05-28JefferiesDowngrade Buy -> Hold
2025-05-27NeedhamDowngrade Buy -> Hold
2025-05-16Chardan CapitalMaintains Buy -> Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 6, 2026
Period
Q1 / 2026
EPS Estimate
-$0.42
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
25.16%
Number of Analysts
15

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
8.10%
EPS (3 Months)
8.10%

Next Earnings Summary

RCKT is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is -0.42 USD and the consensus revenue estimate is 0 USD.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
RCKT revenue by date.RCKT revenue by date.
N/AN/A
51.17%		N/A
217.64%		N/A
78.14%		N/A
81.10%		N/A
78.55%		N/A
58.15%		N/A
32.35%
EBITDA
YoY % growth
RCKT ebitda by date.RCKT ebitda by date.
-20.35M-7.5M
63.14%		-19.57M
-160.93%		-70.83M
-261.93%		-75.72M
-6.90%		-133.15M
-75.85%		-161.88M
-21.58%		-214.87M
-32.73%		-249.361M
-16.05%		-263.83M
-5.80%		-217.491M
17.56%		N/A
30.51%		N/A
-23.69%		N/A
-4.99%		N/AN/AN/AN/AN/A
EBIT
YoY % growth
RCKT ebit by date.RCKT ebit by date.
-20.4M-7.57M
62.89%		-19.77M
-161.16%		-71.16M
-259.94%		-76.15M
-7.01%		-134.3M
-76.36%		-167.25M
-24.53%		-221.14M
-32.22%		-256.459M
-15.97%		-273.205M
-6.53%		-228.516M
16.36%		N/A
13.18%		N/A
0.65%		N/A
-10.55%		N/A
48.56%		N/A
79.97%		N/A
913.38%		N/A
149.99%		N/A
54.76%
Operating Margin
RCKT operating margin by date.RCKT operating margin by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EPS
YoY % growth
RCKT eps by date.RCKT eps by date.
-3.56-6.40
-79.78%		N/A-1.88-1.58
15.96%		-2.51
-58.86%		-2.68
-6.77%		-3.29
-22.76%		-2.94
10.64%		-2.73
7.14%		-1.98
27.47%		N/A
21.60%		N/A
19.57%		N/A
25.16%		N/A
42.14%		N/A
91.98%		N/A
2,092.24%		N/A
129.92%		N/A
65.66%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		-0.42
25.16%		-0.40
31.54%		-0.39
12.28%		-0.37
3.37%		-0.40
5.09%		-0.40
1.52%		-0.42
-5.94%		-0.41
-11.11%
Revenue
Q2Q % growth		27.683K786.165K20.377M5.949M6.841M
24,612.10%		7.436M
845.86%		9.518M
-53.29%
EBITDA
Q2Q % growth		-38.251M
37.70%		-40.018M
35.57%		-42.195M
3.25%		26.563M
180.48%		N/AN/AN/AN/A
EBIT
Q2Q % growth		-45.822M
28.83%		-46.382M
31.47%		-46.42M
11.44%		-28.284M
35.76%		-47.133M
-2.86%		-47.573M
-2.57%		-49.226M
-6.05%		-47.874M
-69.26%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

RCKT Yearly Revenue VS EstimatesRCKT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2024 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
RCKT Yearly EPS VS EstimatesRCKT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -5 -10

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
15.18%
EPS Next 5 Year
14.62%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
6.25%
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

ROCKET PHARMACEUTICALS INC / RCKT Forecast FAQ

What is the price target for RCKT stock?

21 analysts have analysed RCKT and the average price target is 8.37 USD. This implies a price increase of 121.98% is expected in the next year compared to the current price of 3.77.

Can you provide the upcoming earnings date for ROCKET PHARMACEUTICALS INC?

ROCKET PHARMACEUTICALS INC (RCKT) will report earnings on 2026-05-06, after the market close.

What are the consensus estimates for ROCKET PHARMACEUTICALS INC (RCKT) next earnings?

The consensus EPS estimate for the next earnings of ROCKET PHARMACEUTICALS INC (RCKT) is -0.42 USD and the consensus revenue estimate is 0 USD.

How many analysts cover ROCKET PHARMACEUTICALS INC (RCKT) stock?

The number of analysts covering ROCKET PHARMACEUTICALS INC (RCKT) is 21.